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ABSTRACT  
      Based on a number of studies, magnesium sulfate (MgSO4) given after a diffuse axonal injury has 
gained attention as a useful neuroprotective agent .The present study was conducted to examine if 
magnesium sulfate has a therapeutic efficacy and safety in patients with a severe diffuse axonal injury. 
Adult patients admitted within 1 hour of a closed Traumatic Brain Injury (TBI) with a severe diffuse 
axonal injury that met eligibility criteria were randomized into two groups. Our treatment guidelines 
consisted of an initial loading dose of 50 mg/kg magnesium sulfate and then 50 mg/kg QID up to 24 
hours after the trauma. The outcome measures were mortality, GCS, and motor function scores which 
were assessed up to 2 months after the trauma. Magnesium showed a significant positive effect on GCS 
2 months (P=0.03).  Among those in MgSO4 group, motor functioning score improved more than 
control group but this was not statistically significant (P = 0.51). At the end, we have demonstrated that 
administration of magnesium sulfate can have neuroprotective role following severe DAI. 
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INTRODUCTION 
     Traumatic brain injury (TBI) is the biggest 
killer of individuals under 44 years of age. 
Despite this, there is no accepted 
pharmacological intervention for the treatment 
of neurotrauma [1; 2]. DAI is responsible for 
most TBI patients that are severely impaired 
despite the lack of gross parenchymal 
contusions, lacerations, or hematomas [3]. It is 
characterized by multiple small lesions in white 
matter tracts. Patients with DAI are usually in a 
profound coma as a result of injury, do not 
manifest high ICP, and often have a poor 
outcome [4]. The pathophysiology of diffuse 
axonal injury involves a severe angular and 
rotational acceleration and deceleration that 
deliver shear and tensile forces to axons [5]. 
The histological findings of DAI have been well 
described and include disruption and swelling of 
axons, "retraction balls "(swollen proximal ends 
of severed axons), and punctate hemorrhage in 
pons, midbrain, and corpus callosum [6]. Many 
of these abnormalities, including axonal 
severing, are not present initially but develop 
over a course of several hours or days after 
injury [7]. In many cases, it is difficult to 
distinguish an axonal damage due to the 
mechanical shearing (primary injury) from the 
damage caused by biochemical and metabolic 
sequelae of TBI (secondary injury) [8].  
According to in vivo findings, a neuroprotective 
therapy would play a central part in 
pathophysiology of DAI [9]. Experimentally, 
studies from several laboratories have 
documented that serum magnesium and brain 
magnesium are decreased after an experimental 
traumatic brain injury and this decline of 
intracellular Mg is associated with decreased 
cellular phosphate energy stores and the severity 
of neuronal injury [10]. Magnesium 
supplementation improves the outcome whether 
given before, shortly after, or hours after an 
injury. Mg is believed to act presynaptically to 
inhibit the release of excitatory amino acid 
(EAAS) and postsynaptically through non-
competitive voltage-dependent inhibition of N-
metyle-D-asparatate (NMDA) receptor–
mediated Ca release, which is the mechanism 
attributed to neuronal effects [11]. Therefore, 
brain injuries associated with EAA 
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excitotoxicity, such as global ischemia and 
traumatic brain injury, offer opportunities to 
evaluate this mechanism of potential 
neuroprotection by Mg [12]. Unfortunately most 
studies examining the effects of magnesium 
have been limited to the immediate 1-2 week 
period after trauma, making it unclear whether 
the functional improvement observed is relevant 
to a long-term functional outcome or simply 
related to the transient nature of a secondary 
injury [13]. So, we designed this study to test 
the notion that treating a diffuse axonal injury in 
head-injured patients with magnesium would 
improve outcome in short and long term after 
trauma.  
 
MATERIALS AND METHODS 
      Patients with a severe diffuse axonal injury 
who were admitted to Imam Reza hospital, 
Tabriz, from July 2010 to July 2011 were 
studied. Written consent was obtained from all 
the patients. This study was approved by ethic 
committee of Tabriz University of medical 
sciences. Inclusion criteria were: patients older 
than 18 and less than 65 years old, the time gap 
between trauma and admission to the medical 
center not exceeding more than one hour 
preferably. Severe diffuse axonal injury was 
defined as a coma lasting more than 24 hours 
with decerebrate posturing or flaccidity. With 
routine ICU monitoring none of our patients 
recovered in consciousness during the first 24 
hours. In fact they were excluded if they 
recovered. Our exclusion criteria were renal 
failure, pregnancy, seizure, unstable 
cardiovascular state, surgical indication for 
intracranial hematoma evacuation, persistent 
hypotension(systolic Bp<90 mmHg) 
unresponsive to IV administration of fluids, 
refractory systemic hemorrhage requiring blood 
product transfusion, the presence of a traumatic 
subdural hematoma and operative evacuation of 
intracranial hemorrhage. The initial treatment 
consisted of ventilation, antibiotic prophylaxis 
with cefotaxime or ceftriaxone, seizure 
prophylaxis with phenytoin, gastric ulcer 
prophylaxis with ranitidine and urinary 
catheterization done in all patients. The study 
was a double blind randomized clinical trial 
with a placebo control. Randomization was 
stratified by severity and age. Thirty eight 
patients who met the eligibility criteria were 
randomly assigned to our study. Our treatment 
guidelines consisted of an initial intravenous 
loading dose of 50 mg/kg magnesium sulfate 
within one hour after trauma and then 50 mg/kg 
QID magnesium sulfate up to 24 hours after 
trauma. Identical appearing saline was given to 
the control group in the same manner. With 
routine ICU monitoring which was performed in 
all the patient, the safety could be evaluated by 
the continuous monitoring of vital functions, 
blood chemistry, biochemical indices, 
electrocardiogram, invasive arterial blood 
pressure(mean, systolic  and diastolic), and 
round-the-clock input/output measurements. 
During this study, we had no serum creatinine 
up to 1mg/dl. So, there was no need to measure 
the serum magnesium.in more detail, 
Parentrally administered magnesium is cleared 
almost totally by renal excretion, and 
magnesium intoxication is unusual when the 
glomerular filtration rate is maintained or only 
slightly decreased. Adequate urine output is 
usually correlated with preserved glomerular 
filtration rate. That means, magnesium 
excretion is not urine flow dependent, and 
urinary volume per unit time does not predict 
renal function. thus, serum creatinine levels 
must be measured to detect signs of declining 
glomerular filtration rate [21].The outcome was 
evaluated on the basis of some measures 
including mortality, GCS, and motor function 
scores obtained on the first, third, tenth days (or 
at the discharge time after admission). Two 
months after the injury, the participants were 
followed by a phone call for the same measures 
including mortality, motor function and GCS 
scores. Our analysis followed according to the 
treatment principles. Patients who were not 
available for the follow-up were excluded from 
the analysis. So a sample size of thirty eight 
patients was selected randomly in two groups. 
Then the data were collected for three times: at 
the beginning of the study, on the third day, and 
at the discharge time. SPSSTM-17 was used as 
the statistical program. Chi-square test was used 
for qualitative and quantitative variables. We 
used a repeated measuring model (nested 
model) that would do the analysis with a 
Minitab Statistical Package. Our model was 
"Variation of GCS = patients + time + drug 
(time) + error". The level of significance 
emerged to be 0.05. Finally, the results were 
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     Fifty four patients admitted during the study 
timeline and meeting our criteria were 
randomized in two groups. In the test group, 
two patients did not receive MgSO4 due to renal 
failure, four due to refractory systemic 
hemorrhage requiring blood product 
transfusion, and six others were missing for the 
follow-up. In the control group, four patients 
were not available to follow up. The final study 
sample size consisted of thirty eight patients, 
with nineteen in each group. Mean age of 
patients in case and control groups was 34.72 ± 
3.37 and 35.42 ± 2.48 respectively that showed 
no significant difference in terms of age 
between the two groups (P = 0.567). Our results 
showed that the mean of GCS recordings 
conducted at 3 times in the two groups had an 
ascending pattern, but it was not statistically 
significant in the MgSO4 group (P > 0.05) But 
when they were followed up for 2 months it 
became statistically significant (P = 0.038) 
(Table 1) (Figure 1). Among those in the 
MgSO4 group, the motor function scores 
improved more than the scores in the control 
group, but this was not statistically significant 
(P = 0.512) (Table 2). The effect of MgSO4 on 
the improvement of mortality rate was not 
statistically significant in both groups (P = 0.5).  
 
Table 1. Mean GCS variations in drug and placebo group 
at different times (Data are presented as Mean ± SD.) 
Time MgSO4 Placebo 
Beginning 5.105 ± 0.215 5.211 ± 0.249 
3 days 7.632 ± 0.873 6.947 ± 0.807 
Discharge 10.895 ± 1.169 8.526 ±1.173 
60 days 12.474 ± 1.276 9.580 ±1.226 
 
Table2. Mean motor variations in drug and placebo groups 
at different times(Data are presented as Mean ± SD.) 
Time MgSO4 Placebo 
Beginning 3.000 ± 0.153 3.211 ± 0.249 
3 days 3.947 ± 0.386 3.842 ± 0.434 
Discharge 4.947 ± 0.510 4.263 ± 0.534 
60 days 5.053 ± 0.516 4.421 ± 0.548 
 
 
Figure 1. Mean GCS variations in drug and placebo 
group at different times 
DISCUSSION 
     The original concept of neuroprotection 
involved the initiation of treatment before the 
onset of the event, and was aimed at minimizing 
the intensity of an insult or its immediate effects 
on the brain by interrupting the harmful 
cascades of biochemical events [14]. 
Observation in humans suggests that abnormal 
Mg homeostasis occurs in the setting of a 
critical illness particularly an acute brain injury. 
Correlations between the severity of 
neurological deficits and early measure of 
serum Mg have been observed following 
traumatic brain injuries [15]. Hypomagnesemia 
was shown to be more prevalent in patients with 
a head  injury than in control group members 
without a brain injury. The injury severity in 
patients with a traumatic brain injury correlated 
linearly with the level of systemic ionized Mg 
depletion [16]. The classical concept that DAI is 
due to the mechanical rapture of axons 
incompatible with regeneration or repair has 
now been abandoned. Neurons can at least 
partially regenerate their axonal anatomy. This 
conforms to clinical observations that patients 
with hallmark features on CT of DAI can 
recover with modern neurocritical care. 
Furthermore, laboratory studies have shown that 
DAI can take up to 48 hours to become fully 
established and is , thus, amenable to 
therapeutic intervention [17].   Heath et al. 
demonstrated a potential therapeutic window of 
24 hours after trauma in rats. In their 
experiments, Mg therapy significantly improved 
the motor outcome when administered up to 24 
hours after the injury, with an earlier 
administration resulting in better pronounced 
improvement [18]. In this study, it was 
demonstrated that repeated administration 
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beyond 24 hours does not further improve the 
outcome. We have used a maintenance 
intravenous regimen up to 24 hours after injury. 
Previous results have shown that administration 
of magnesium sulfate at either a low or a high 
dose cannot improve neurologic outcome, at 
least when given at a low dose. We encounter a 
poorer outcome at a high dose, and a higher 
mortality occurs [19]. On the other hand, the 
data have shown that the hyperactivity of the 
glutamate NMDA receptor occurs within the 
first hour after an experimental brain injury, but 
the stimulation of NMDA receptors within 24 h 
and 48 h after the injury improves the outcome. 
Continuous high concentrations of magnesium 
in this subacute period would attenuate this 
NMDA stimulation and plausibly adversely 
affect recovery [20]. Therefore, our intervention 
consisted of an initial intravenous loading dose 
of magnesium which was followed by a non-
continuous infusion to maintain the magnesium 
concentration. In this study we tested only a few 
of the possible combinations of dose, start time, 
and duration of treatment. However, the 
regimen used in this study was within the range 
used in positive preclinical studies. MgSO4 
started within 1h and showed a positive effect 
on the motor function score. The objective of 
our study was to achieve a safe regimen with a 
favorable outcome. Although our results 
demonstrated that MgSO4 significantly 
improves GCS score within 2 months, we have 
not achieved this result about motor function 
scores or mortality rate. It should be noted that 
GCS scores may fluctuate soon after injury, 
with some patients deteriorating and others 
improving. From a perspective of prognosis, the 
assessment of GCS should, therefore, be related 
to the given time period, depending on the 
intent for the estimating of prognosis. 
 
CONCLUSION 
      Since cell-deteriorating processes are 
already known in DAI, and laboratory findings 
confirm the 48-hour period of axonal 
stabilization, it is suggested that the parenteral 
administration of magnesium sulfate appear to 
have a favorable influence on GCS score at 2 
months, when administered to patients within 
24 hour of closed traumatic brain injury without 
any apparent significant adverse effects.      
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